Yazar "Gurlertop, Yekta" seçeneğine göre listele
Listeleniyor 1 - 7 / 7
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Atrial fibrillation in the setting of takotsubo cardiomyopathy: Just the tip of the iceberg?(Elsevier Ireland Ltd, 2018) Yalta, Kenan; Taylan, Gokay; Gurlertop, Yekta[Abstract Not Available]Öğe Cancer Therapy-Related Pulmonary Hypertension: A Review of Mechanisms and Implications for Clinical Practice(Kare Publ, 2023) Gurdogan, Muhammet; Demir, Melik; Yalta, Kenan; Gurlertop, YektaCancer therapy-related pulmonary hypertension is a rare yet potentially fatal cardiotoxicity. However, it is a reversible cause of pulmonary hypertension if detected in its early stages. Cancer therapy-related pulmonary hypertension has been encountered in patients using tyrosine kinase inhibitors, particularly dasatinib. However, it is also well known that many agents used in cancer treatment such as alkylating agents, proteasome inhibitors, thoracic radiation exposure, and immune checkpoint inhibitors are particularly associated with pulmonary hypertension evolution. In case that history, symptoms, and clinical findings suggest a potential cancer therapy-related pulmonary hypertension, echocardiography is considered as the initial tool to detect pulmonary hypertension. If the possibility of pulmonary hypertension is high based on echocardiographic data, cancer treatment, as the initial step, should be discontinued due to its potential risks and other causes for pulmonary hypertension should be investigated thoroughly. Right heart catheterization should be the next step to establish the final diagnosis, and medical management, where appropriate, should be started without delay in these patients according to their pulmonary hypertension subgroup. There exists limited information regarding the diagnostic and management strategies of cancer therapy-related pulmonary hypertension in the current guidelines. In this review article, we aim to present current literature data on the mechanisms and management of cancer therapy-related pulmonary hypertension along with its follow-up algorithm in the setting of cardio-oncology practice.Öğe Coexistence of Anti-PD1-Induced Immune Myocarditis and Complete Atrioventricular Block: A Case Report(Excerpta Medica Inc-Elsevier Science Inc, 2023) Gurdogan, Muhammet; Yalta, Kenan; Gurlertop, Yekta; Karahan, Furkan; Bulburu, Irem Bilge; Kocyogot, Beliz; Ustabasioglu, Fethi EmreThe present report describes the late recovery of an emerging complete atrioventricular (AV block) in a patient with immune check point inhibitor-related myocarditis following a period of immunosuppresive therapy. Therefore, decision-making for permanent pace-maker implantation should be implemented after a substantial period of time owing to the potential recovery of bradyarrhythmic complications in similar cases. (c) 2023 Elsevier Inc. All rights reserved.Öğe Late coronary ischemic syndromes associated with transcatheter aortic valve implantation: A review of mechanistic and clinical aspects(Elsevier, 2018) Yalta, Kenan; Zorkun, Cafer; Yilmaztepe, Mustafa; Gurlertop, YektaIn the past years, transcatheter aortic valve implantation (TAVI) has emerged as a promising option for the treatment of aortic valve pathologies particularly in the the presence of surgically high-risk situations. Importantly, a variety of specific procedural complications including acute coronary osteal occlusion, though very rare, has been reported in major clinical studies. However, little is known about the late impact of TAVI on coronary system at the macro and microvascular levels. On the other hand, clinical studies as well as real life experiences have shown variable rates of acute coronary syndrome (ACS) readmissions among TAVI recipients in the short and long terms. Within this context, it may be suggested that even though late coronary ischemic events arising after TAVI, to some extent, appears to be spontaneous or attributable to certain stressors, TAVI may also have the potential to directly account for, accelerate or contribute to the evolution of these ischemic events on follow-up. Accordingly, the present review primarily focuses on potential association of TAVI with late coronary ischemic syndromes along with a particular emphasis on its mechanistic basis and clinical implications among TAVI recipients. (C) 2018 Published by Elsevier B.V. on behalf of Cardiological Society of India.Öğe Mechanically expanding transcatheter aortic valves: pros and cons of a unique device technology(Ame Publishing Company, 2018) Yalta, Kenan; Gurdogan, Muhammet; Zorkun, Cafer; Gurlertop, Yekta[Abstract Not Available]Öğe Persistent diastolic dysfunction and its implications in the setting of takotsubo cardiomyopathy(Elsevier Ireland Ltd, 2018) Yalta, Kenan; Gurlertop, Yekta; Taylan, Gokay[Abstract Not Available]Öğe Serum copeptin might improve risk stratification and management of aortic valve stenosis: a review of pathophysiological insights and practical implications(Sage Publications Ltd, 2019) Yalta, Kenan; Palabiyik, Orkide; Gurdogan, Muhammet; Gurlertop, YektaOver recent decades, the prevalence of aortic valve stenosis (AVS) has been constantly increasing possibly owing to the aging of general population. Severe AVS as determined by an aortic valve area (AVA) of <1 cm(2) has been regarded as a serious clinical condition potentially associated with a variety of adverse outcomes, including sudden cardiac death (SCD). However, patients with severe AVS (in the absence of overt high-risk features) are usually evaluated and managed exclusively based on symptomatology or imperfect prognostic tools including exercise testing and biomarkers, with a potential risk of mismanagement, suggesting the need for further objective risk stratifiers in this setting. Within this context, copeptin (C-terminal pro-vasopressin), a novel neurohormone widely considered as the surrogate marker of the arginine-vasopressin (AVP) system, may potentially serve as a reliable prognostic and therapeutic guide (e.g. timing of aortic valvular intervention) in patients with severe AVS largely based on its hemodynamic, fibrogenic as well as autonomic implications in these patients. Accordingly, the present paper aims to discuss clinical and pathophysiological implications of copeptin in the setting of AVS along with a summary of biomarkers and other prognostic tools used in this setting.